• Journal of Chest Surgery
• /
• 제37권3호
• /
• pp.279-281
• /
• 2004

베체트병은 구강 생식기의 궤양, 안구와 피부 병변을 주 증상으로하고 심혈관계, 호흡기계, 소화기계, 중추신경계, 비뇨기계를 침범하여 다양한 증상을 나타낼 수 있다. 베체트병에서 경동맥류와 장천공의 동반은 드문 경우로, 병리소견과 병력상 베체트병으로 진단 받은 환자에서 상기 병증에 대한 수술을 시행하였기에 보고하는 바이다.

• Pediatric Gastroenterology, Hepatology & Nutrition
• /
• 제11권1호
• /
• pp.80-83
• /
• 2008

소아 베체트병은 상당히 드문 질환으로 전체 베체트병의 약 2~3%에 해당한다. 이 중 장 점막과 관련된 경우는 2~50%까지 다양하게 보고되나, 대부분이 40~50대 성인에서 보고되는 내용이며 소아 베체트병 환자에서 장 천공이 보고된 증례는 극히 드물다. 본 증례는 4년 9개월된 남아로, 베체트병을 진단받은 후 약물 치료하며 추적 관찰 중, 지속되는 복통이 있어 시행한 대장 내시경상에 다발성 장점막 궤양이 관찰되었고, 이후 스테로이드 용량 감량하며 경과 관찰하던 중 장 천공이 발생하여 수술한 1예를 경험하였기에 보고하는 바이다.

• Gut and Liver
• /
• 제12권6호
• /
• pp.623-632
• /
• 2018

Intestinal Behçet's disease is a rare, immune-mediated chronic intestinal inflammatory disease; therefore, clinical trials to optimize the management and treatment of patients are scarce. Moreover, intestinal Behçet's disease is difficult to treat and often requires surgery because of the failure of conventional medical treatment. Administration of anti-tumor necrosis factor-${\alpha}$, a potential therapeutic strategy, is currently under active clinical investigation, and evidence of its effectiveness for both intestinal Behçet's disease and inflammatory bowel diseases has been accumulating. Here, we review updated data on current experiences and outcomes after the administration of anti-tumor necrosis factor-${\alpha}$ for the treatment of intestinal Behçet's disease. In addition to infliximab and adalimumab, which are the most commonly used agents, we describe agents such as golimumab, etanercept, and certolizumab pegol, which have recently been shown to be effective in refractory intestinal Behçet's disease. This review also discusses safety issues associated with anti-tumor necrosis factor-${\alpha}$, including vulnerability to infections and malignancy.

• The Korean Journal of Pain
• /
• 제22권1호
• /
• pp.104-106
• /
• 2009

Behcet's disease is a chronic relapsing vasculitis characterized by recurrent aphthous oral and genital ulcers with uveitis. Multiple organs can be involved. Entero-Behcet's disease is often uncontrollable, relapsing, and can cause acute intestinal bleeding, fistula formation, or perforation. Corticosteroids, immunosuppressors, and colchicines are used to treat Entero-Behcet's disease with varying degree of success. Thalidomide may also be feasible. We present a 29-year-old male Entero-Behcet's patient suffering from abdominal pain, diarrhea, and back pain. He did not respond to prior treatments, but responded to thalidomide.

• Gut and Liver
• /
• 제12권6호
• /
• pp.674-681
• /
• 2018

Background/Aims: The cumulative surgery rate and postoperative relapse of intestinal Behçet's disease (BD) have been reported to be high. This study aimed to establish a scoring system based on follow-up endoscopic findings that can predict intestinal BD recurrence after surgery. Methods: Fifty-four patients with intestinal BD who underwent surgery due to bowel complications and underwent follow-up colonoscopy were retrospectively investigated. Their clinical data, including colonoscopic findings, were retrieved. Classification and regression tree analysis was used to develop an appropriate endoscopic classification model that can explain the postsurgical recurrence of intestinal BD most accurately based on the following classification: e0, no lesions; e1, solitary ulcer <20 mm in size; e2, solitary ulcer ${\geq}20mm$ in size; and e3, multiple ulcers regardless of size. Results: Clinical relapse occurred in 37 patients (68.5%). Among 38 patients with colonoscopic recurrence, only 29 patients had clinically relapsed. Multivariate analysis identified higher disease activity index for intestinal BD at colonoscopy (hazard ratio [HR], 1.013; 95% confidence interval [CI], 1.005 to 1.021; p=0.002) and colonoscopic recurrence (HR, 2.829; 95% CI, 1.223 to 6.545; p=0.015) as independent risk factors for clinical relapse of intestinal BD. Endoscopic findings were classified into four groups, and multivariate analysis showed that the endoscopic score was an independent risk factor of clinical relapse (p=0.012). The risk of clinical relapse was higher in the e3 group compared to the e0 group (HR, 6.284; 95% CI, 2.036 to 19.391; p=0.001). Conclusions: This new endoscopic scoring system could predict clinical relapse in patients after surgical resection of intestinal BD.